Maven Securities
TLSIW icon

Maven Securities’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Maven Securities’s Portfolio TLSIW Stock Details TLSIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-48,665
Closed -$25K – 1104
2021
Q4 		$25K Sell
48,665
-2,626
-5% -$2.41K ﹤0.01% 807
2021
Q3 		$42K Buy
51,291
+16,666
+48% +$15.5K ﹤0.01% 1014
2021
Q2 		$41K Buy
+34,625
New +$34.2K ﹤0.01% 997

Other funds holding TLSIW

Mangrove Partners
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Radcliffe Capital Management
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
Angelo Gordon & Co
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return
Spring Creek Capital
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
Vestcor Inc
Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.56% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Maven Securities's TLSIW Position: Q1 2022 in Review

Maven Securities sold out of TriSalus Life Sciences Warrant (TLSIW) in Q1 2022, closing a stake of 48,665 shares — an estimated $25K sold.

Maven Securities first reported a position in TLSIW in Q2 2021 and held it in 3 quarters. The position peaked at $42K in Q3 2021. 26 funds tracked by Wall St. Rank hold TLSIW as of Q1 2022.

  • Maven Securities reported no remaining TriSalus Life Sciences Warrant position as of Q1 2022 after selling out during the quarter.
  • Maven Securities sold 48,665 TriSalus Life Sciences Warrant shares in Q1 2022, an estimated $25K.
  • Maven Securities first reported a position in TriSalus Life Sciences Warrant in Q2 2021 and held it in 3 quarters.
  • Maven Securities's TriSalus Life Sciences Warrant position peaked at $42K in Q3 2021.
  • 26 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q1 2022.

Based on Maven Securities's 13F filing for Q1 2022, filed 16 May 2022.